Evidence map›Paper›PMID 39140289›Full record

ArticleFuture oncology (London, England)2024

A perioperative study of Safusidenib in patients with

Sarah A Cain, Monique Topp, Mark Rosenthal, Robert Tobler, Saskia Freytag, Sarah A Best, James R Whittle, Katharine J Drummond

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sarah A CainDepartment of Neurosurgery, Royal Melbourne Hospital, Parkville, 3052, Australia.ORCID 0000-0002-6610-4617
Monique ToppDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, 3000, Australia.
Mark RosenthalDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, 3000, Australia.
Robert ToblerPersonalised Oncology Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, 3052, Australia.ORCID 0009-0002-6983-556X
Saskia FreytagPersonalised Oncology Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, 3052, Australia.ORCID 0000-0002-2185-7068
Sarah A BestPersonalised Oncology Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, 3052, Australia.ORCID 0000-0002-4232-9432
James R WhittleDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, 3000, Australia.ORCID 0000-0002-4740-2037
Katharine J DrummondDepartment of Neurosurgery, Royal Melbourne Hospital, Parkville, 3052, Australia.ORCID 0000-0002-8152-2120

Funding

AnHeart TherapeuticsState Government of Victoria The Brain Perioperative Clinical Trial Program (Br)Victorian Cancer Agency MCRF22003
6 · The paper itself

Abstract

This is a single arm, open label perioperative trial to assess the feasibility, pharmacokinetics and pharmacodynamics of treatment with safusidenib following biopsy, and prior to surgical resection in patients with

Indexed as

Brain NeoplasmsGliomaIsocitrate DehydrogenaseMutationAdultAgedAntineoplastic AgentsFemaleHumansMaleMiddle AgedPerioperative CareProgression-Free SurvivalAntineoplastic AgentsIDH1 protein, humanIsocitrate DehydrogenaseAB-218IDH1isocitrate dehydrogenase 1low grade gliomaPhase 0safusidenibwindow of opportunity

Identifiers

PMID39140289
PMCPMC11534100

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.